Search Results - "Saunders, Jesse"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    Characterization of the Impaired Glucose Homeostasis Produced in C57BL/6 Mice by Chronic Exposure to Arsenic and High-Fat Diet by Paul, David S., Walton, Felecia S., Saunders, R. Jesse, Stýblo, Miroslav

    Published in Environmental health perspectives (01-08-2011)
    “…Background: Type 2 diabetes is characterized by glucose intolerance and insulin resistance. Obesity is the leading cause of type 2 diabetes. Growing evidence…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    Methylation of arsenic by recombinant human wild-type arsenic (+3 oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorph: Role of glutathione by Ding, Lan, Saunders, R. Jesse, Drobná, Zuzana, Walton, Felecia S., Xun, Pencheng, Thomas, David J., Stýblo, Miroslav

    Published in Toxicology and applied pharmacology (01-10-2012)
    “…Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the key enzyme in the pathway for methylation of arsenicals. A common polymorphism in the AS3MT gene…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Arsenic (+ 3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice by Hughes, Michael F., Edwards, Brenda C., Herbin-Davis, Karen M., Saunders, Jesse, Styblo, Miroslav, Thomas, David J.

    Published in Toxicology and applied pharmacology (15-12-2010)
    “…Arsenic (+ 3 oxidation state) methyltransferase ( As3mt) catalyzes formation of mono-, di-, and tri-methylated metabolites of inorganic arsenic. Distribution…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Knockout of arsenic (+3 oxidation state) methyltransferase is associated with adverse metabolic phenotype in mice: the role of sex and arsenic exposure by Douillet, Christelle, Huang, Madelyn C., Saunders, R. Jesse, Dover, Ellen N., Zhang, Chongben, Stýblo, Miroslav

    Published in Archives of toxicology (01-07-2017)
    “…Susceptibility to toxic effects of inorganic arsenic (iAs) depends, in part, on efficiency of iAs methylation by arsenic (+3 oxidation state) methyltransferase…”
    Get full text
    Journal Article
  10. 10

    Metabolomic profiles of arsenic (+3 oxidation state) methyltransferase knockout mice: effect of sex and arsenic exposure by Huang, Madelyn C., Douillet, Christelle, Su, Mingming, Zhou, Kejun, Wu, Tao, Chen, Wenlian, Galanko, Joseph A., Drobná, Zuzana, Saunders, R. Jesse, Martin, Elizabeth, Fry, Rebecca C., Jia, Wei, Stýblo, Miroslav

    Published in Archives of toxicology (01-01-2017)
    “…Arsenic (+3 oxidation state) methyltransferase (As3mt) is the key enzyme in the pathway for methylation of inorganic arsenic (iAs). Altered As3mt expression…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets by Douillet, Christelle, Currier, Jenna, Saunders, Jesse, Bodnar, Wanda M., Matoušek, Tomáš, Stýblo, Miroslav

    Published in Toxicology and applied pharmacology (15-02-2013)
    “…Epidemiologic evidence has linked chronic exposure to inorganic arsenic (iAs) with an increased prevalence of diabetes mellitus. Laboratory studies have…”
    Get full text
    Journal Article
  13. 13

    The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients by Ghiuzeli, Cristina M., Stýblo, Miroslav, Saunders, Jesse, Calabro, Anthony, Budman, Daniel, Allen, Steven, Devoe, Craig, Dhingra, Radhika

    Published in Leukemia & lymphoma (23-02-2022)
    “…Arsenic trioxide (ATO) treats Acute Promyelocytic Leukemia (APL). ATO is converted from inorganic arsenic (iAs) to methylated (MAs) and dimethylated (DMAs)…”
    Get full text
    Journal Article
  14. 14

    Abstract 5053: Arsenic trioxide metabolism in patients with acute promyelocytic leukemia by Khan, Mohammad T., Tariq, Sara, Ghiuzeli, Cristina M., Styblo, Miroslav, Saunders, Jesse, Calabro, Anthony, Kohn, Nina, Budman, Daniel, Allen, Steven, Devoe, Craig

    Published in Cancer research (Chicago, Ill.) (01-07-2017)
    “…BACKGROUND: Arsenic trioxide (ATO) is a mainstay of therapy for Acute Promyelocytic Leukemia (APL). Its long term effects and pharmacokinetics have not been…”
    Get full text
    Journal Article
  15. 15

    The epigenetic effects of a high prenatal folate intake in male mouse fetuses exposed in utero to arsenic by Tsang, Verne, Fry, Rebecca C., Niculescu, Mihai D., Rager, Julia E., Saunders, Jesse, Paul, David S., Zeisel, Steven H., Waalkes, Michael P., Stýblo, Miroslav, Drobná, Zuzana

    Published in Toxicology and applied pharmacology (01-11-2012)
    “…Inorganic arsenic (iAs) is a complete transplacental carcinogen in mice. Previous studies have demonstrated that in utero exposure to iAs promotes cancer in…”
    Get full text
    Journal Article
  16. 16

    Phase I and pharmacokinetic trial of the antitemolerase agent KML001 (KML) and cisplatin (CDDP) in advanced solid tumors by Edelman, Martin J., Feliciano, Josephine Louella, Styblo, Miroslav, Liu, Tao, Lapidus, Rena G., Saunders, Jesse, Gobburu, Joga

    Published in Journal of clinical oncology (20-05-2013)
    “…Abstract only 2515 Background: Telomerase is overexpressed in most solid tumors and rarely expressed in adult tissues and is therefore a promising target. We…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Arsenic trioxide: Pharmacokinetics in acute promyelocytic leukemia (APL) patients by Ghiuzeli, Cristina Maria, Calabro, Anthony, Saunders, Randall Jesse, Budman, Daniel R., Styblo, Miroslav, Devoe, Craig E., Allen, Steven L.

    Published in Journal of clinical oncology (20-05-2013)
    “…Abstract only 7055 Background: Arsenic (As) has significantly increased survival for APL patients. As and its metabolites’ effects on cell proliferation,…”
    Get full text
    Journal Article
  19. 19